100th つないで、進む FRONTIERS IN LIFE SCIENCE

検索の使い方

Esophagus Squamous Cell Carcinoma And Metastatic Carcinoma Tissue Array, With Adjacent Tissue And Adjacent Normal Tissue|ヒト組織アレイ

掲載日情報：2015/08/14 現在Webページ番号：174540

ティッシューアレイドットコム /
TissueArray.Com LLC
[メーカー略称：USB]

US Biomax社は、豊富なラインナップの組織アレイ、組織切片(凍結、FFPE)を提供しているメーカーです。
US Biomax社のヒト組織アレイ(Esophagus Squamous Cell Carcinoma And Metastatic Carcinoma Tissue Array, With Adjacent Tissue And Adjacent Normal Tissue, Including TNM And Pathology Grade, 120 Cases/200 Cores、replaced By ES2001a)をご紹介します。

※ヒト組織アレイは、ドナーからインフォームドコンセントを取得した組織を使用しています。
※ドナーの組織は、HIV、Hepatitis B、Hepatitis Cが陰性であることを確認しています。
※本製品は研究用です。研究用以外には使用できません。

カートに商品を
追加しました。

ヒト組織アレイの価格

[在庫・価格 ：2024年05月16日 19時15分現在]

※ 表示されている納期は弊社に在庫が無く、取り寄せた場合の納期目安となります。
詳細 商品名
  • 商品コード
  • メーカー
  • 包装
  • 価格
  • 在庫
  • 法規制等
 納期 文献数
Esophagus cancer tissue array, with metastasis tissue, adjacent tissue and adjacent normal tissue, including TNM and・・・
 2～3週間 ※※ 表示されている納期は弊社に在庫がなく、取り寄せた場合の目安納期となります。 0
説明文
法規制等
保存条件 室温,暗所保存 法規備考
掲載カタログ

製品記事 TissueArray.Com社 組織アレイ(Tissue array) 選択ガイド
関連記事 TissueArray.Com社 パラフィン組織スライド／組織アレイの仕様変更につきまして

[在庫・価格 ：2024年05月16日 19時15分現在]

※ 表示されている納期は弊社に在庫が無く、取り寄せた場合の納期目安となります。

Esophagus cancer tissue array, with metastasis tissue, adjacent tissue and adjacent normal tissue, including TNM and・・・

文献数： 0

説明文
法規制等
保存条件 室温,暗所保存 法規備考
掲載カタログ

製品記事 TissueArray.Com社 組織アレイ(Tissue array) 選択ガイド
関連記事 TissueArray.Com社 パラフィン組織スライド／組織アレイの仕様変更につきまして

目次に戻る

カートに商品を
追加しました。

ヒト組織アレイの特長

Microarray Panel: Esophagus squamous cell carcinoma and metastatic carcinoma tissue microarray, containing 120 cases of squamous cell carcinoma, 40 metastasis carcinoma, 30 adjacent tissue, 10 adjacent normal tissue, single or duplicate cores per case
Cores: 200
組織アレイ
Cases: 120
Layout: 16 cols × 13 rows
Core Diameter: 1 mm
Thickness: 5 µm
Quality Control: Anti-Cytokeratin (CK) confirmed
Applications:

Routine histology procedures including ImmunoHistochemistry (IHC) and In Situ Hybridization (ISH), protocols which can be found on our support page.
Notes: Unless specified, all TMA slides are not coated with extra layer of paraffin (tissue cores can be easily seen on the glass), so there is no need to bake, can be directly put into xylene for de-paraffin procedure.

*Tissue Microarray Slide Types:

  • Unstained: unstained paraffin tissue microarray slide.
  • Trial: tissue microarray trial slide. 10% - 25% of cores missing. Good for titrating antibody dilution and experiment conditions. Limited numbers are available, to 2 per item per order. Test slides (tissue arrays with catalog numbers ending with 241 or 242) are recommended as a substitute.
  • H and E: Hematoxylin and Eosin stained tissue array slide.

目次に戻る

カートに商品を
追加しました。

ヒト組織アレイの仕様表

Pos No. Sex Age Organ Pathology diagnosis Grade Stage TNM Type †
A1 1 M 54 Esophagus Squamous cell carcinoma 1 III T3N1M0 Malignant
A2 2 M 58 Esophagus Squamous cell carcinoma 1 III T3N1M0 Malignant
A3 3 F 64 Esophagus Squamous cell carcinoma 1–2 IV T2N1M1a Malignant
A4 4 M 43 Esophagus Squamous cell carcinoma with foreign-body giant cell reaction 1 IIa T3N0M0 Malignant
A5 5 M 71 Esophagus Squamous cell carcinoma 1 III T3N1M0 Malignant
A6 6 F 54 Esophagus Squamous cell carcinoma 1 III T3N1M0 Malignant
A7 7 F 58 Esophagus Squamous cell carcinoma 1 III T3N1M0 Malignant
A8 8 M 69 Esophagus Squamous cell carcinoma 1 III T3N1M0 Malignant
A9 9 M 60 Esophagus Squamous cell carcinoma 1 IIb T2N1M0 Malignant
A10 10 F 57 Esophagus Squamous cell carcinoma 1 III T3N1M0 Malignant
A11 11 M 60 Esophagus Squamous cell carcinoma 1 III T3N1M0 Malignant
A12 12 M 55 Esophagus Squamous cell carcinoma 1 IIb T2N1M0 Malignant
A13 13 F 63 Esophagus Squamous cell carcinoma 1 IIa T3N0M0 Malignant
A14 14 M 70 Esophagus Squamous cell carcinoma (fibrous connective tissue) – IIa T3N0M0 Malignant
A15 15 F 36 Esophagus Squamous cell carcinoma 1 IIa T3N0M0 Malignant
A16 16 M 58 Esophagus Squamous cell carcinoma 1 III T3N1M0 Malignant
B1 17 M 51 Esophagus Squamous cell carcinoma 1 III T3N1M0 Malignant
B2 18 M 73 Esophagus Squamous cell carcinoma 1 IIb T1N1M0 Malignant
B3 19 M 64 Esophagus Squamous cell carcinoma 1 IIa T3N0M0 Malignant
B4 20 M 59 Esophagus Squamous cell carcinoma 1 IIa T3N0M0 Malignant
B5 21 F 68 Esophagus Squamous cell carcinoma 1 IIa T3N0M0 Malignant
B6 22 M 73 Esophagus Squamous cell carcinoma 1 IIa T2N0M0 Malignant
B7 23 M 63 Esophagus Squamous cell carcinoma 1 IIa T3N0M0 Malignant
B8 24 M 59 Esophagus Squamous cell carcinoma 1 IIa T3N0M0 Malignant
B9 25 M 58 Esophagus Squamous cell carcinoma 1 IIa T3N0M0 Malignant
B10 26 M 50 Esophagus Squamous cell carcinoma 1 IIa T3N0M0 Malignant
B11 27 F 60 Esophagus Squamous cell carcinoma 1 IIa T3N0M0 Malignant
B12 28 M 72 Esophagus Squamous cell carcinoma 1 IIa T2N0M0 Malignant
B13 29 M 58 Esophagus Squamous cell carcinoma 1 IIa T3N0M0 Malignant
B14 30 M 59 Esophagus Squamous cell carcinoma 1 IIa T3N0M0 Malignant
B15 31 M 60 Esophagus Squamous cell carcinoma 1 IIa T2N0M0 Malignant
B16 32 M 58 Esophagus Squamous cell carcinoma 1 IIa T2N0M0 Malignant
C1 33 M 56 Esophagus Squamous cell carcinoma (sparse) with keratinization 1 IIa T3N0M0 Malignant
C2 34 M 53 Esophagus Squamous cell carcinoma 1 IIa T3N0M0 Malignant
C3 35 M 68 Esophagus Squamous cell carcinoma 1 IIa T3N0M0 Malignant
C4 36 F 55 Esophagus Squamous cell carcinoma 1 IIa T3N0M0 Malignant
C5 37 M 60 Esophagus Squamous cell carcinoma 1 IIa T3N0M0 Malignant
C6 38 F 51 Esophagus Squamous cell carcinoma 1 IIa T3N0M0 Malignant
C7 39 M 69 Esophagus Squamous cell carcinoma 1 IIa T3N0M0 Malignant
C8 40 M 59 Esophagus Squamous cell carcinoma 1 IIa T3N0M0 Malignant
C9 41 M 49 Esophagus Squamous cell carcinoma 2 IIa T3N0M0 Malignant
C10 42 M 51 Esophagus Squamous cell carcinoma 2 IIa T2N0M0 Malignant
C11 43 M 56 Esophagus Squamous cell carcinoma 1–2 IIb T2N1M0 Malignant
C12 44 M 62 Esophagus Squamous cell carcinoma 2 III T3N1M0 Malignant
C13 45 F 68 Esophagus Squamous cell carcinoma 2 III T3N1M0 Malignant
C14 46 M 57 Esophagus Squamous cell carcinoma 2 III T3N1M0 Malignant
C15 47 M 50 Esophagus Squamous cell carcinoma 2 IIb T2N1M0 Malignant
C16 48 F 51 Esophagus Squamous cell carcinoma 2 IIa T3N0M0 Malignant
D1 49 M 65 Esophagus Squamous cell carcinoma 2 III T3N1M0 Malignant
D2 50 M 53 Esophagus Squamous cell carcinoma 2 IIa T3N0M0 Malignant
D3 51 M 58 Esophagus Squamous cell carcinoma 2 III T3N1M0 Malignant
D4 52 F 65 Esophagus Squamous cell carcinoma 2 III T3N1M0 Malignant
D5 53 F 51 Esophagus Squamous cell carcinoma 2 III T3N1M0 Malignant
D6 54 M 75 Esophagus Squamous cell carcinoma 2 III T3N1M0 Malignant
D7 55 M 57 Esophagus Squamous cell carcinoma 2 IIa T3N0M0 Malignant
D8 56 M 57 Esophagus Squamous cell carcinoma 2 III T3N1M0 Malignant
D9 57 M 52 Esophagus Squamous cell carcinoma 2 IIa T3N0M0 Malignant
D10 58 M 51 Esophagus Squamous cell carcinoma 2 IIa T3N0M0 Malignant
D11 59 F 61 Esophagus Squamous cell carcinoma 2 III T3N1M0 Malignant
D12 60 M 65 Esophagus Squamous cell carcinoma 2 IIa T3N0M0 Malignant
D13 61 F 69 Esophagus Squamous cell carcinoma 2 IIa T2N0M0 Malignant
D14 62 F 48 Esophagus Squamous cell carcinoma 2 IIa T3N0M0 Malignant
D15 63 M 59 Esophagus Squamous cell carcinoma 2 IIa T3N0M0 Malignant
D16 64 F 63 Esophagus Squamous cell carcinoma 2 IIa T3N0M0 Malignant
E1 65 F 60 Esophagus Squamous cell carcinoma 2 III T3N1M0 Malignant
E2 66 M 62 Esophagus Squamous cell carcinoma 2 IIa T2N0M0 Malignant
E3 67 F 53 Esophagus Squamous cell carcinoma 2 IIa T2N0M0 Malignant
E4 68 M 51 Esophagus Squamous cell carcinoma 2 IIa T2N0M0 Malignant
E5 69 F 66 Esophagus Squamous cell carcinoma 2 III T3N1M0 Malignant
E6 70 M 74 Esophagus Squamous cell carcinoma 2 IIa T3N0M0 Malignant
E7 71 M 53 Esophagus Squamous cell carcinoma (smooth muscle) – IIa T3N0M0 Malignant
E8 72 M 61 Esophagus Squamous cell carcinoma 1–2 IIa T3N0M0 Malignant
E9 73 F 64 Esophagus Squamous cell carcinoma 2 III T3N1M0 Malignant
E10 74 F 52 Esophagus Squamous cell carcinoma 2 IIa T2N0M0 Malignant
E11 75 M 67 Esophagus Squamous cell carcinoma 2 III T3N1M0 Malignant
E12 76 F 64 Esophagus Squamous cell carcinoma 2 III T3N1M0 Malignant
E13 77 M 54 Esophagus Squamous cell carcinoma 2 III T3N1M0 Malignant
E14 78 F 65 Esophagus Squamous cell carcinoma 2 III T3N1M0 Malignant
E15 79 M 51 Esophagus Squamous cell carcinoma (hyperplastic lymphatic tissue sparse) – III T3N1M0 Malignant
E16 80 M 50 Esophagus Squamous cell carcinoma 2 IIb T2N1M0 Malignant
F1 81 M 56 Esophagus Squamous cell carcinoma 2 I T1N0M0 Malignant
F2 82 M 44 Esophagus Squamous cell carcinoma 2–3 IIa T3N0M0 Malignant
F3 83 F 70 Esophagus Squamous cell carcinoma 3 IIa T2N0M0 Malignant
F4 84 M 71 Esophagus Squamous cell carcinoma 3 IIb T2N1M0 Malignant
F5 85 F 64 Esophagus Squamous cell carcinoma 2–3 III T3N1M0 Malignant
F6 86 M 53 Esophagus Squamous cell carcinoma 3 III T3N1M0 Malignant
F7 87 M 53 Esophagus Squamous cell carcinoma 3 IIb T2N1M0 Malignant
F8 88 M 49 Esophagus Squamous cell carcinoma 3 IIa T2N0M0 Malignant
F9 89 M 50 Esophagus Squamous cell carcinoma 3 IIa T3N0M0 Malignant
F10 90 F 48 Esophagus Squamous cell carcinoma 2 IIa T3N0M0 Malignant
F11 91 F 38 Esophagus Squamous cell carcinoma 2–3 III T3N1M0 Malignant
F12 92 M 64 Esophagus Squamous cell carcinoma 2 IIa T3N0M0 Malignant
F13 93 M 50 Esophagus Squamous cell carcinoma 3 IIa T3N0M0 Malignant
F14 94 F 60 Esophagus Squamous cell carcinoma 3 IIa T3N0M0 Malignant
F15 95 F 53 Esophagus Squamous cell carcinoma 3 IIa T3N0M0 Malignant
F16 96 M 70 Esophagus Squamous cell carcinoma 3 III T3N1M0 Malignant
G1 97 M 45 Esophagus Squamous cell carcinoma 3 IIa T3N0M0 Malignant
G2 98 M 63 Esophagus Squamous cell carcinoma (lymphatic tissue) – III T3N1M0 Malignant
G3 99 M 32 Esophagus Squamous cell carcinoma 3 III T3N1M0 Malignant
G4 100 M 62 Esophagus Squamous cell carcinoma 3 IIa T3N0M0 Malignant
G5 101 F 52 Esophagus Squamous cell carcinoma 3 IIa T3N0M0 Malignant
G6 102 F 53 Esophagus Squamous cell carcinoma 3 III T3N1M0 Malignant
G7 103 M 50 Esophagus Squamous cell carcinoma 3 IIa T3N0M0 Malignant
G8 104 M 64 Esophagus Squamous cell carcinoma 3 IIa T3N0M0 Malignant
G9 105 F 53 Esophagus Squamous cell carcinoma 3 IIa T3N0M0 Malignant
G10 106 F 48 Esophagus Squamous cell carcinoma 3 I T1N0M0 Malignant
G11 107 M 58 Esophagus Squamous cell carcinoma 3 III T3N1M0 Malignant
G12 108 M 55 Esophagus Squamous cell carcinoma 3 III T3N1M0 Malignant
G13 109 M 67 Esophagus Squamous cell carcinoma 3 IIb T2N1M0 Malignant
G14 110 M 56 Esophagus Squamous cell carcinoma 3 I T1N0M0 Malignant
G15 111 M 70 Esophagus Squamous cell carcinoma 3 IIa T3N0M0 Malignant
G16 112 F 52 Esophagus Squamous cell carcinoma (sparse) 3 IIa T3N0M0 Malignant
H1 113 M 56 Esophagus Squamous cell carcinoma 2–3 IIa T2N0M0 Malignant
H2 114 M 55 Esophagus Squamous cell carcinoma 3 IIa T3N0M0 Malignant
H3 115 F 59 Esophagus Squamous cell carcinoma 3 IIb T2N1M0 Malignant
H4 116 M 51 Esophagus Squamous cell carcinoma 3 IIa T3N0M0 Malignant
H5 117 M 52 Esophagus Squamous cell carcinoma 3 I T1N0M0 Malignant
H6 118 M 53 Esophagus Squamous cell carcinoma 3 IIa T2N0M0 Malignant
H7 119 M 62 Esophagus Squamous cell carcinoma 3 IIa T2N0M0 Malignant
H8 120 M 53 Esophagus Squamous cell carcinoma 3 IIa T2N0M0 Malignant
H9 121 F 54 Lymph node Metastatic squamous cell carcinoma of No. 06 1 – – MET.
H10 122 M 58 Lymph node Metastatic squamous cell carcinoma of No. 02 1 – – MET.
H11 123 M 69 Lymph node Metastatic squamous cell carcinoma of No. 08 1 – – MET.
H12 124 M 58 Lymph node Metastatic squamous cell carcinoma of No. 16 1 – – MET.
H13 125 M 54 Lymph node Metastatic squamous cell carcinoma of No. 01 1 – – MET.
H14 126 F 57 Lymph node Metastatic squamous cell carcinoma of No. 10 2 – – MET.
H15 127 M 71 Lymph node Metastatic squamous cell carcinoma (sparse) of No. 84 2 – – MET.
H16 128 M 53 Lymph node Metastatic squamous cell carcinoma of No. 50 1–2 – – MET.
I1 129 M 55 Lymph node Metastatic squamous cell carcinoma of No. 12 1–2 – – MET.
I2 130 M 58 Lymph node Metastatic squamous cell carcinoma (adipose tissue and blood vessel) of No. 51 – – – MET.
I3 131 M 73 Lymph node Metastatic squamous cell carcinoma of No. 18 2 – – MET.
I4 132 F 65 Lymph node Metastatic squamous cell carcinoma (sparse) of No. 52 1 – – MET.
I5 133 M 60 Lymph node Metastatic squamous cell carcinoma of No. 11 2 – – MET.
I6 134 M 50 Lymph node Metastatic squamous cell carcinoma of No. 47 1 – – MET.
I7 135 F 64 Lymph node Metastatic squamous cell carcinoma with necrosis of No. 03 1 – – MET.
I8 136 M 51 Lymph node Metastatic squamous cell carcinoma of No. 17 2 – – MET.
I9 137 M 60 Lymph node Metastatic squamous cell carcinoma (sparse) of No. 09 – – – MET.
I10 138 M 75 Lymph node Metastatic squamous cell carcinoma of No. 54 3 – – MET.
I11 139 F 68 Lymph node Metastatic squamous cell carcinoma of No. 45 2–3 – – MET.
I12 140 M 65 Lymph node Metastatic squamous cell carcinoma of No. 49 3 – – MET.
I13 141 F 65 Lymph node Metastatic squamous cell carcinoma (fibrofatty tissue) of No. 78 – – – MET.
I14 142 F 64 Lymph node Metastatic squamous cell carcinoma of No. 76 2 – – MET.
I15 143 F 64 Lymph node Metastatic squamous cell carcinoma of No. 85 2–3 – – MET.
I16 144 F 38 Lymph node Metastatic squamous cell carcinoma (cornification, necrosis and squamous cell carcinoma cell) of No. 91 – – – MET.
J1 145 M 53 Lymph node Metastatic squamous cell carcinoma of No. 86 2–3 – – MET.
J2 146 M 51 Lymph node Metastatic squamous cell carcinoma of No. 79 2 – – MET.
J3 147 M 67 Lymph node Metastatic squamous cell carcinoma with necrosis of No. 75 2 – – MET.
J4 148 M 50 Lymph node Metastatic squamous cell carcinoma of No. 80 3 – – MET.
J5 149 F 58 Lymph node Metastatic squamous cell carcinoma of No. 07 3 – – MET.
J6 150 M 62 Lymph node Metastatic squamous cell carcinoma of No. 44 3 – – MET.
J7 151 M 70 Lymph node Metastatic squamous cell carcinoma of No. 96 3 – – MET.
J8 152 M 32 Lymph node Metastatic squamous cell carcinoma of No. 99 3 – – MET.
J9 153 F 53 Lymph node Metastatic squamous cell carcinoma of No. 102 3 – – MET.
J10 154 M 53 Lymph node Metastatic squamous cell carcinoma of No. 87 3 – – MET.
J11 155 F 51 Lymph node Metastatic squamous cell carcinoma of No. 53 3 – – MET.
J12 156 M 54 Lymph node Metastatic squamous cell carcinoma of No. 77 3 – – MET.
J13 157 M 55 Lymph node Metastatic squamous cell carcinoma of No. 108 3 – – MET.
J14 158 F 59 Lymph node Metastatic squamous cell carcinoma of No. 115 3 – – MET.
J15 159 M 67 Lymph node Metastatic squamous cell carcinoma of No. 109 3 – – MET.
J16 160 M 71 Lymph node Metastatic squamous cell carcinoma of No. 05 3 – – MET.
K1 161 F 52 Esophagus Cancer adjacent tissue (esophagus tissue) of No. 101 – – – AT
K2 162 M 68 Esophagus Cancer adjacent tissue (reflux esophagitis) of No. 35 – – – AT
K3 163 F 63 Esophagus Cancer adjacent tissue (fibrofatty tissue) of No. 13 – – – AT
K4 164 M 59 Esophagus Cancer adjacent tissue (reflux esophagitis) of No. 30 – – – AT
K5 165 M 43 Esophagus Cancer adjacent tissue (chronic esophagitis) of No. 04 – – – AT
K6 166 M 69 Esophagus Cancer adjacent tissue (reflux esophagitis with epithelial proliferation) of No. 39 – – – AT
K7 167 F 51 Esophagus Cancer adjacent tissue (esophagus tissue) of No. 38 – – – AT
K8 168 F 60 Esophagus Cancer adjacent tissue (reflux esophagitis) of No. 27 – – – AT
K9 169 M 70 Esophagus Cancer adjacent tissue (reflux esophagitis) of No. 14 – – – AT
K10 170 F 68 Esophagus Cancer adjacent tissue (esophagus tissue) of No. 21 – – – AT
K11 171 M 60 Esophagus Cancer adjacent tissue (reflux esophagitis) of No. 37 – – – AT
K12 172 M 58 Esophagus Cancer adjacent tissue (chronic esophagitis with epithelial proliferation) of No. 25 – – – AT
K13 173 F 55 Esophagus Cancer adjacent tissue (chronic esophagitis) of No. 36 – – – AT
K14 174 M 63 Esophagus Cancer adjacent tissue (chronic esophagitis and local hyperplasia) of No. 23 – – – AT
K15 175 M 73 Esophagus Cancer adjacent tissue (esophagus tissue) of No. 22 – – – AT
K16 176 M 59 Esophagus Cancer adjacent tissue (chronic esophagitis) of No. 24 – – – AT
L1 177 M 58 Esophagus Cancer adjacent tissue (esophageal mucosa sparse and smooth muscle) of No. 29 – – – AT
L2 178 M 50 Esophagus Cancer adjacent tissue (chronic esophagitis with epithelial proliferation) of No. 89 – – – AT
L3 179 M 51 Esophagus Cancer adjacent tissue (reflux esophagitis with epithelial proliferation) of No. 58 – – – AT
L4 180 F 61 Esophagus Cancer adjacent tissue (chronic esophagitis) of No. 59 – – – AT
L5 181 F 69 Esophagus Cancer adjacent tissue (esophagus tissue) of No. 61 – – – AT
L6 182 M 62 Esophagus Cancer adjacent tissue (reflux esophagitis) of No. 100 – – – AT
L7 183 M 50 Esophagus Cancer adjacent tissue (chronic esophagitis with epithelial proliferation) of No. 103 – – – AT
L8 184 M 51 Esophagus Cancer adjacent tissue (esophagus tissue) of No. 68 – – – AT
L9 185 F 52 Esophagus Cancer adjacent tissue (esophagus tissue) of No. 112 – – – AT
L10 186 M 59 Esophagus Cancer adjacent tissue (esophagus tissue) of No. 63 – – – AT
L11 187 F 48 Esophagus Cancer adjacent tissue (fibrous connective tissue) of No. 62 – – – AT
L12 188 F 53 Esophagus Cancer adjacent tissue (smooth muscle) of No. 67 – – – AT
L13 189 F 48 Esophagus Cancer adjacent tissue (fibrous tissue and smooth mscle) of No. 90 – – – AT
L14 190 M 49 Esophagus Cancer adjacent tissue (esophageal mucosa) of No. 88 – – – AT
L15 191 M 58 Esophagus Cancer adjacent normal esophagus tissue (fibrous tissue and smooth muscle) of No. 29 – – – NAT
L16 192 F 48 Esophagus Cancer adjacent normal esophagus tissue (reflux esophagitis with epithelial proliferation) of No. 106 – – – NAT
M1 193 M 64 Esophagus Cancer adjacent normal esophagus tissue of No. 104 – – – NAT
M2 194 M 50 Esophagus Cancer adjacent normal esophagus tissue of No. 89 – – – NAT
M3 195 F 48 Esophagus Cancer adjacent normal esophageal mucosa tissue of No. 90 – – – NAT
M4 196 M 58 Esophagus Cancer adjacent normal esophagus tissue of No. 25 – – – NAT
M5 197 F 55 Esophagus Cancer adjacent normal esophagus tissue (chronic esophagitis with local epithelial proliferation) of No. 36 – – – NAT
M6 198 M 60 Esophagus Cancer adjacent normal esophagus tissue of No. 37 – – – NAT
M7 199 F 51 Esophagus Cancer adjacent normal esophagus tissue (chronic esophagitis with epithelial proliferation) of No. 38 – – – NAT
M8 200 M 69 Esophagus Cancer adjacent normal esophagus tissue of No. 39 – – – NAT

*For precise diagnosis, refer to pathology description.

目次に戻る

カートに商品を
追加しました。

ヒト組織アレイのFAQ

US BIOMAX社ヒト組織アレイのFAQはこちら。

目次に戻る

カートに商品を
追加しました。

お問い合わせ先

（テクニカルサポート 試薬担当）

reagent@funakoshi.co.jp

製品情報は掲載時点のものですが、価格表内の価格については随時最新のものに更新されます。お問い合わせいただくタイミングにより製品情報・価格などは変更されている場合があります。
表示価格に、消費税等は含まれていません。一部価格が予告なく変更される場合がありますので、あらかじめご了承下さい。